Bristol Myers Squibb’s 2026 adjusted EPS outlook includes net impact from acquired IPR&D charges and licensing
The 2026 adjusted EPS outlook range includes a net impact from acquired IPR&D charges and licensing income.
The 2026 adjusted EPS outlook range includes a net impact from acquired IPR&D charges and licensing income.